Skip to content
etf.net

GNMX

GradeCChicago Board Options Exchange

Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF

Themes · Corgi Funds · Inception 2026-05-05 · SEC filings

$36.92−0.61 (−1.63%)

As of Sep 23, 2026, 1:43 PM EDT

History starts May 6, 2026.History starts May 6, 2026.History starts May 6, 2026.
Intraday session: down, 4 prints from 37.53 to 36.92. Range 36.92 to 37.53. Use the arrow keys to read each point.$37.00$37.20$37.40$37.6010 AM12 PM2 PM4 PM
Expense ratio
0.35%
Fund size
$3M
1Y return
—
Yield · Last 12 months
—
Holdings
30
Volume · 30D
0M sh
NAV per share
$36.85
52W range
low $23.88high $37.65

The ETF.net GNMX Grade

C

40/ 100

Rank 11 of 17 in Biotech & Genomics⁠

Confidence Medium

Six-pillar profile for GNMX. Scores out of 100: Cost 81, Risk 82, Mission not scored, Tradability 0, Holdings 54, Durability 0. Strongest: Risk (82). Weakest: Durability (0). Based on 5 of 6 pillars.
F< 25
D≥ 25
C≥ 40
B≥ 55
A≥ 70

Score 40 of 100 sits in the C band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E. A structural cap ceilings this fund at 40, so B and A are out of reach.

Ceiling 40 · B and A out of reach

The pillars earned56This cap took−16Published score40 Grade C

  • Cost

    What you pay to own it — the expense ratio plus trading frictions, ranked within its category.
    AScore 81
    Category rank4/17 · top 24%

  • Mission

    How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.
    Not scored
    —

  • Risk

    How violently it can move — volatility, drawdown depth, and downside capture versus its category.
    AScore 82
    Category rank1/17 · top 6%

  • Tradability

    How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.
    FScore 0
    Category rank17/17 · bottom quartile

  • Holdings

    What it actually owns — the quality, breadth, and concentration of the underlying portfolio.
    CScore 54
    Category rank10/17 · mid-pack

  • Durability

    Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.
    FScore 0
    Category rank17/17 · bottom quartile

Graded as of Sep 22, 2026 · Based on 5 of 6 pillars

GNMX Holdings

As of Sep 20, 2026, 8:16 AM
Asset class
Stocks
Holdings
30
Top-10 weight
45%
Largest holding
TMO8.6%

Sectors

  • Health Care97.6%
  • Technology2.4%

Geography

  • United States91.24%
  • Netherlands3.62%
  • Denmark2.95%
  • Switzerland2.19%
The fund’s holdings, weight-ordered — page 1 of 4.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001TMOThermo Fisher Scientific Inc8.62%360$235K369
002MRNAModerna Inc7.05%1,245$192K240
003VRTXVertex Pharmaceuticals Inc5.89%315$160K417
004ILMNIllumina Inc4.36%495$119K305
005GHGuardant Health Inc3.86%585$105K171
006TXG10X Genomics Inc3.42%1,215$93K136
007RVMDRevolution Medicines Inc3.27%465$89K169
008GMABGenmab A/S2.91%2,280$79K26
009INCYIncyte Corp2.90%630$79K364
010TWSTTwist Bioscience Corp2.86%465$78K123
011ALNYAlnylam Pharmaceuticals Inc2.64%300$72K258
012—First American Government Obligations Fund 12/01/20312.62%71,373$71K625
013IOVAIovance Biotherapeutics Inc2.30%6,105$63K80
014BMRNBioMarin Pharmaceutical Inc2.22%945$60K181
015TECHBio-Techne Corp2.20%825$60K184

Showing 1–15 of 58 holdings

GNMX Performance

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

GNMX$13,422
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$10,415
Jun 22, 2026 to Sep 22, 2026. GNMX $13,422. SPY $10,415. Use the arrow keys to read each point.$9,503$11,608$13,713Jun 2026Aug 2026Sep 2026

Jun 22, 2026 – Sep 22, 2026

Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for GNMX. Periods over one year show the average yearly return.
PeriodGNMX
Year to dateFund launched this year—
1 month+5.1%
3 months+34.2%
1 yearFund is under 1 year old—
3 yearsFund is under 3 years old—per year
5 yearsFund is under 5 years old—per year
10 yearsFund is under 10 years old—per year

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for GNMX
YearReturn barGNMX
2026 YTD+46.4%

History from May 6, 2026

GNMX in the news

ETF.net Research hasn’t filed on GNMX yet — coverage lands here as it’s written.

GNMX Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Sep 22, 2026.
—Last 12 months
Payout per share
—Last 12 months

Listed May 2026. No distributions yet.

GNMX Risk

How much the fund’s monthly returns vary, scaled to a year.
—
Launched May 2026; fills in after 12 months
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
—
Launched May 2026; fills in after 12 months
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
—
Launched May 2026; fills in after 12 months
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
2.45
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

GNMX Cost

Expense ratio0.35%
  • The middle half of Biotech & Genomics funds
  • Median 0.47%

1 of the 15 Biotech & Genomics funds charge less.

GNMX costs $35.00 a year on $10,000. The median Biotech & Genomics fund costs $47.00.